- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00117533
Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Recombinant IFN alfa possesses anti-viral and immunomodulatory effects and has been shown to be effective in chronic hepatitis B [Davis et al. 1989; Bisceclie et al, 1989]. Interferon alfa is also one of the approved treatments for chronic hepatitis B. Administration of IFN alfa-2b to adults leads to disappearance of HBV DNA with or without HBeAg seroconversion in 30-50% of patients, which is two to three times above the rate of yearly spontaneous HBeAg seroconversion (10-15%). Normalization of serum ALT occurs in most cases. Loss of HBsAg is observed in 10-15% of Caucasian patients during the prolonged post-treatment follow-up period. Recently, studies suggested that a higher proportion of patients receiving pegylated IFN could achieve HBeAg seroconversion and control of HBV replication [Marcellin et al, 2004; Lau et al, 2004; Jensen et al, 2004].
RBV is another antiviral nucleotide analogue with few adverse effects [Sidwell et al, 1972; Patterson et al, 1990]. RBV alone can modestly inhibit HDV or HBV replication [Choi et al, 1989]. The beneficial effect of combined IFN plus RBV in the treatment of chronic hepatitis B has also been shown in previous studies [Cotonat et al, 2000]. Why RBV can greatly enhance the treatment efficacy is not clear. It had been shown that ribavirin could inhibit interleukin-4, an inhibitor of cytotoxic T lymphocyte activity, and preserves the interleukin-2 and gamma IFN activities. Other studies revealed that the enhanced efficacy was associated with HBV- or other virus-specific type 1 cytokine-mediated T helper cell responses [Cramp et al, 2000; Tam et al, 1999; Hultgren et al, 1998; Fang et al, 2002; Fang et al, 2000; Rico et al, 2001]. Thus, the combination therapy may augment virus-specific cytotoxic T lymphocytes and non-specific immune response, and effectively shift the immune responses to the more potent antiviral type 1 T-helper profile [Hultgren et al, 1998].
HDV, like HCV, is a RNA virus. Indeed, RBV had also been shown to be active against HDV replication in cell cultures [Choi et al, 1989]. The investigators therefore hypothesize that pegylated IFN alfa-2b in combination with RBV can yield an efficacy in chronic hepatitis D patients who are dually infected by HBV. The purpose of this protocol is to test this hypothesis. A previous study found that high-dose IFN may improve the efficacy for chronic hepatitis D patients. Another pilot study using IFN alfa plus RBV also demonstrated that the seroclearance of HCV RNA was not affected by HBV coinfection [Liu et al, 2003]. The investigators thus use pegylated IFN alfa-2b in combination with RBV for the treatment of patients with dual chronic HDV and HBV infection.
The treatment choice for chronic hepatitis D was not clarified till now. In this proposal, the dosage and duration for the combination regimen are decided mainly by the experience from the treatment of chronic hepatitis B and chronic hepatitis C.
The investigators recent study using ribavirin and interferon (IFN) combination therapy for dual chronic hepatitis B and C suggested that combining ribavirin 1,200 mg daily for 6 months, together with 6 million units (MU) IFN-alpha 2a thrice weekly for 12 weeks and then 3 MU for another 12 weeks was effective for the clearance of HCV RNA [Liu et al, 2003]. Twenty-four patients with chronic hepatitis seropositive for both hepatitis B surface antigen and antibody to HCV received ribavirin 1,200 mg daily for 6 months, together with 6 million units (MU) IFN-alpha 2a thrice weekly for 12 weeks and then 3 MU for another 12 weeks. The serum HCV clearance rate was 43% 24 weeks posttreatment. The serum ALT normalization rate was 43% 24 weeks posttreatment. In hepatitis B and C dually infected patients, combination IFN with ribavirin can achieve a sustained HCV clearance rate comparable with hepatitis C alone. Furthermore, a previous study revealed that a 12-week RBV therapy was not effective for patients with chronic hepatitis B [Kakumu et al, 1993]. Therefore, a 24-week course of combination therapy pegylated IFN+RBV will be used.
Increased RBV dosage has been considered a contributory factor to the better efficacy in treating refractory genotype HCV. For example, recent studies suggested that using RBV 800 mg daily is adequate to treat HCV genotype non-1 while the standard dosage of RBV is required to treat HCV genotype 1 [NIH 2002]. The investigators thus propose to use RBV 1000-1200 mg daily according to the body weight of the patient.
Studientyp
Einschreibung
Phase
- Phase 4
Kontakte und Standorte
Studienkontakt
- Name: Pei-Jer Chen, M.D., Ph.D.
- Telefonnummer: 7072 886-2-23123456
- E-Mail: peijer@ha.mc.ntu.edu.tw
Studienorte
-
-
-
Taipei, Taiwan, 100
- Rekrutierung
- National Taiwan University Hospital
-
Taipei, Taiwan, 100
- Noch keine Rekrutierung
- National Taiwan University
-
Hauptermittler:
- Pei-Jer Chen, M.D., Ph.D.
-
Kontakt:
- Pei-Jer Chen, M.D.; Ph.D.
- Telefonnummer: 7072 886-2-23123456
- E-Mail: peijer@ha.mc.ntu.edu.tw
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Be positive for both anti-HDV and HBsAg for more than 6 months
- Present with elevated serum ALT levels at least 1.5 times the upper limit of normal, documented on two occasions (at least one month apart), within six months prior to enrollment
- Be HDV RNA positive by PCR (sensitivity: 103 copies/mL) [Yamashiro et al, 2004]
- Be HBV DNA positive by PCR
- Present with liver biopsy findings compatible with the diagnosis of chronic liver disease (the liver biopsy needs to be taken within 52 weeks prior to enrollment)
- Have adequate liver reserve (defined as equal to or better than Child-Pugh Class A)
- Present with WBC ≥3000/mm3, ANC ≥1500/mm3, and platelet ≥80,000/mm3
- Be able to and likely to attend regularly for treatment and follow-up
- Give their written informed consent
- Be negative for urine pregnancy test (for females of childbearing potential), documented once within the screening period and again within 24 hours prior to the first dose of study drug
- All male patients with female partners of childbearing age should use a barrier method of contraception
- All female patients of childbearing potential must use two reliable forms of effective contraception
Exclusion Criteria:
- Drug addicts or have any history or histological evidence of alcohol abuse, or currently receive prescriptions that may cause hepatotoxicity
- Have decompensated cirrhosis as coded by Child-Pugh classification (i.e. history of ascites, history of bleeding from esophageal varices, severe portal hypertension, serum albumin <30 g/l, serum bilirubin >30 mg/l)
- Present with WBC <3000/mm3, ANC <1500/mm3, or platelets <90,000/mm3
- Present with hemoglobin <12.0 gm/dl for female and <13.0 gm/dl for male
- Have been treated with immunosuppressive therapy within the past six months (e.g. steroids, azathioprine, cyclophosphamide)
- Have renal insufficiency (serum creatinine >150 μmol/l)
- Have clotting abnormalities which preclude a liver biopsy
- Have evidence of any serious neurological dysfunction
- Have obesity or diabetes mellitus-induced liver disease
- Have serological evidence of autoimmune chronic liver disease (e.g. antinuclear antibody titers >1:320, and/or smooth muscle antibody titers>1:160)
- Hemophiliacs
- Have evidence of inheritable disorders such as haemochromatosis, alpha-1-antitrypsin deficiency or Wilson's disease
- Have been exposed to hepatotoxic substances which might be the cause of hepatitis
- Pregnant, lactating or not practicing an adequate form of birth control, such as oral contraceptives or intrauterine devices
- Seropositive for anti-HIV or anti-HCV
- Have serious psychological or psychiatric problems disrupting daily activities
- Have AFP (alpha-fetoprotein) greater than 20 ng/ml; in case of elevated AFP, abdomen ultrasonography is required to exclude the possibility of HCC
- Have serious heart diseases (coronary heart disease, etc)
- Have a history of asthma or drug allergy which may lead to hypersensitivity to ribavirin
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
---|
the efficacy of 24-week pegylated IFN alfa-2b plus RBV for SVR of HDV in patients with dual chronic hepatitis D and B
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
---|
the efficacy of pegylated IFN alfa-2b plus RBV in patients with dual chronic hepatitis D and B on: The biochemical response rate
|
The degree of histologic change
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Pei-Jer Chen, M.D., Ph.D., National Taiwan University Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Hepatitis, viral, menschlich
- Hepadnaviridae-Infektionen
- DNA-Virusinfektionen
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis D
- Hepatitis D, chronisch
- Hepatitis B, chronisch
- Hepatitis, chronisch
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Antimetaboliten
- Antineoplastische Mittel
- Ribavirin
- Interferon alpha-2
Andere Studien-ID-Nummern
- 930904
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Chronische Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNoch keine Rekrutierung
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRekrutierungChronische Hepatitis b | Zirrhose durch Hepatitis BChina
-
Nanfang Hospital of Southern Medical UniversityRekrutierung
-
IlDong Pharmaceutical Co LtdRekrutierungChronische Hepatitis bKorea, Republik von
-
Antios Therapeutics, IncBeendetChronische Hepatitis bVereinigte Staaten
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unbekannt
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi Hospital... und andere MitarbeiterRekrutierungPatienten mit chronischer Hepatitis b stellen nach Absetzen des Nukleosidanalogs auf tAf um (CHANGE)Chronische Hepatitis b | Hepatitis-B-ReaktivierungTaiwan
-
Mahidol UniversityUnbekanntChronische Hepatitis B, HBsAg, Hepatitis-B-ImpfstoffThailand
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnbekanntChronische Hepatitis b
-
Tongji HospitalGilead SciencesRekrutierung
Klinische Studien zur pegylated IFN alfa-2b plus ribavirin
-
ANRS, Emerging Infectious DiseasesFlamel TechnologiesUnbekannt
-
Tibotec BVBAAbgeschlossenChronische Hepatitis CFrankreich, Spanien, Belgien, Deutschland, Österreich, Niederlande
-
University of Modena and Reggio EmiliaMerck Sharp & Dohme LLCUnbekanntMenopause | Chronische Hepatitis CItalien
-
University Health Network, TorontoSchering-PloughBeendetChronische Hepatitis CKanada
-
Merck Sharp & Dohme LLCBeendet
-
Merck Sharp & Dohme LLCBeendet
-
Prof. Facchinetti FabioMerck Sharp & Dohme LLCAbgeschlossen
-
Hoffmann-La RocheAbgeschlossenHepatitis C, chronischBelgien, Frankreich, Deutschland, Schweden, Schweiz, Truthahn, Griechenland, Irland, Taiwan, Estland, Ungarn, Italien, Rumänien, Vereinigtes Königreich, Serbien, Marokko, Portugal, Saudi-Arabien, Ägypten, Pakistan, Libanon, Mazedonien... und mehr
-
Columbia UniversityMerck Sharp & Dohme LLCZurückgezogenNierenerkrankung im Endstadium | Hepatitis-C-Infektion
-
Azienda Ospedaliero-Universitaria di ParmaAbgeschlossenChronische Hepatitis CItalien